Patterson Companies Inc header image

Patterson Companies Inc

PDCO

Equity

ISIN US7033951036 / Valor 1896660

NASDAQ (2024-11-21)
USD 20.28+1.10%

Patterson Companies Inc
UMushroom community rating:

star star star star star
0.00 0 votes No rating yet
NegativeNeutralPositive

About company

Patterson Companies Inc is a company that specializes in providing products, technologies, services, and business solutions to the animal and oral health markets. With a comprehensive portfolio and distribution network, the company is known for its dedication to serving these specific industries. The company's success is attributed to its passionate and focused team of professionals who work tirelessly to meet the needs of their customers in the animal and oral health sectors.

Summarized from source with an LLMView SourceSector: Healthcare

Latest Results (20.08.2024):

Net Sales

Patterson Companies Inc. reported consolidated net sales of $1.72 billion for the fourth quarter of fiscal 2024, marking a slight increase of 0.1 percent compared to the same period last year. Internal sales, adjusted for currency translation and other factors, decreased by 0.5 percent year-over-year.

Net Income

For the fourth quarter of fiscal 2024, Patterson Companies Inc. reported net income attributable to the company of $67.0 million, or $0.74 per diluted share. This is a decrease from the $75.0 million, or $0.77 per diluted share, reported in the fourth quarter of fiscal 2023.

Dental Segment

The Dental segment of Patterson Companies Inc. reported net sales of $657.8 million for the fourth quarter of fiscal 2024. Internal sales of dental consumables increased by 3.7 percent year-over-year, while internal sales of equipment and value-added services decreased by 11.9 percent and 11.0 percent, respectively.

Animal Health Segment

In the fourth quarter of fiscal 2024, the Animal Health segment reported net sales of $1.06 billion. Internal sales in this segment grew by 2.5 percent year-over-year, driven by a 2.5 percent increase in consumables and a 15.0 percent increase in value-added services, despite a 4.0 percent decline in equipment sales.

Fiscal 2025 Guidance

Patterson Companies Inc. has issued its fiscal 2025 earnings guidance, projecting GAAP earnings to be in the range of $2.00 to $2.10 per diluted share. Non-GAAP adjusted earnings are expected to be between $2.33 and $2.43 per diluted share, excluding deal amortization expenses and other adjustments.

Summarized from source with an LLMView Source

Key figures

-37.2%1Y
-38.9%3Y
6.46%5Y

Performance

36.6%1Y
32.4%3Y
39.6%5Y

Volatility

Market cap

1741 M

Market cap (USD)

Daily traded volume (Shares)

233,152

Daily traded volume (Shares)

1 day high/low

20.46 / 19.84

1 day high/low (USD)

52 weeks high/low

0.00 / 0.00

52 weeks high/low (USD)

Dividend ex-date

01 January, 2022

Dividend ex-date

Dividend

0.00

Dividend (USD)

Dividend yield (p.a.)

0.00%

Dividend yield (p.a.)

0.002022
0.002023
0.002024

Est dividend (USD)

0.00%2022
0.00%2023
0.00%2024

Est dividend yield

P/E ratio

10.00

P/E ratio

00.002022
00.002023
00.002024

Est P/E ratio

EPS

0.00

EPS (USD)

0.002022
0.002023
0.002024

Est EPS (USD)

Ratings & reviews

star star star star star

0.00

0 votes
Performance:
starstarstarstarstar
0.00
Innovation:
starstarstarstarstar
0.00
Society:
starstarstarstarstar
0.00
Nature:
starstarstarstarstar
0.00

EQUITIES OF THE SAME SECTOR

LeMaitre Vascular inc
LeMaitre Vascular inc LeMaitre Vascular inc Valor: 2755054
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
2.35%USD 105.87
Apellis Pharmaceuticals Inc
Apellis Pharmaceuticals Inc Apellis Pharmaceuticals Inc Valor: 30132056
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.95%USD 27.75
ICU Medical Inc
ICU Medical Inc ICU Medical Inc Valor: 940704
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.75%USD 168.84
CRISPR Therapeutics Ltd
CRISPR Therapeutics Ltd CRISPR Therapeutics Ltd Valor: 33408113
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.05%USD 46.29
Surgery Partners Inc
Surgery Partners Inc Surgery Partners Inc Valor: 29308003
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
3.73%USD 23.35
Merit Medical Systems Inc
Merit Medical Systems Inc Merit Medical Systems Inc Valor: 951136
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.91%USD 105.03
Premier Inc
Premier Inc Premier Inc Valor: 22227168
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.85%USD 22.42
Lantheus Holdings Inc
Lantheus Holdings Inc Lantheus Holdings Inc Valor: 24784644
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
1.01%USD 87.32
Arrowhead Pharmaceuticals Inc
Arrowhead Pharmaceuticals Inc Arrowhead Pharmaceuticals Inc Valor: 32193461
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
-2.30%USD 18.28
Evotec SE
Evotec SE Evotec SE Valor: 3979578
starstarstarstarstar

Annual Return

-50%0%+50%

Risk level

110
0.94%USD 5.35